LY2062430

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for LY2062430, covering 2009-10-07 to 2012-12-13. Get the full timeline:

Most recent: Clinical Trial Update: Effect of LY2062430 on the Progression of Alzheimer's Disease [Phase 3]